Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...
Eli Lilly has lined up another deal in the radiopharmaceutical ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy.
Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...